Celaphon To Acquire Ception Therapeutics
Cephalon Inc. (Nasdaq: CEPH) has exercised an option to acquire Ception Therapeutics Inc., a Malvern, Pa.-based drug company whose lead candidates are anti-inflammatories. The deal was originally signed in early 2008, with Cephalon making a $100 million upfront payment, and agreeing to pay another $250 million if it chose to exercise the acquisition option. Ception has raised around $88 million in VC funding, from firms like Essex Woodlands Health Ventures, Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.
25 February 2010•5 mins read
